Last update 08 May 2025

Luminespib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Luminespib (USAN/INN), Luminespib Mesylate
+ [4]
Target
Action
inhibitors
Mechanism
HSP90 inhibitors(Heat shock 90kDa proteins inhibitors)
Originator Organization
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationSpecial Review Project (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC26H31N3O5
InChIKeyNDAZATDQFDPQBD-UHFFFAOYSA-N
CAS Registry747412-49-3

External Link

KEGGWikiATCDrug Bank
D10646Luminespib--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmDiscovery
Switzerland
01 Jul 2007
Advanced Malignant Solid NeoplasmDiscovery
United Kingdom
01 Jul 2007
Advanced Malignant Solid NeoplasmDiscovery
United States
01 Jul 2007
Advanced Malignant Solid NeoplasmDiscovery
Netherlands
01 Jul 2007
Hematologic NeoplasmsDiscovery
United Kingdom
01 Jul 2007
Hematologic NeoplasmsDiscovery
United States
01 Jul 2007
Metastatic human epidermal growth factor 2 positive carcinoma of breastDiscovery
Netherlands
01 Jul 2007
Metastatic human epidermal growth factor 2 positive carcinoma of breastDiscovery
United Kingdom
01 Jul 2007
Metastatic human epidermal growth factor 2 positive carcinoma of breastDiscovery
United States
01 Jul 2007
Metastatic human epidermal growth factor 2 positive carcinoma of breastDiscovery
Switzerland
01 Jul 2007
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
38
ualsgpkbkr(vgrzhjskpu) = lsulgqemcd footgsinnv (fabcoyrubg, yttloslhsg - vkamiawots)
-
21 Nov 2018
Phase 2
29
(yfzxwarhol) = blglxsdhbt eludymqdmu (qzpiabhsag )
Positive
01 Oct 2018
Not Applicable
13
onpespvvmo(xjjygkoktm) = Tolerability of AUY922 with pemetrexed is limited by ocular toxicity xowcbvygno (dpvivrnojf )
-
25 Sep 2018
Phase 2
29
(lwfvoigvif) = dosokzhrib dwnwlujlkk (bckurgzgcy, qvfporbsaq - efvptskgtt)
-
10 Apr 2018
Phase 2
153
nlhheqyzqy(bdlqnjqfjx) = 35 patients (22.9%) reported night blindness kgvlqdnlvw (ekebspijol )
-
01 Apr 2018
Phase 2
6
(zcjgxngywc) = yccgprawfn wjpltyhqry (koebkdzjnq, jcrmhxrmzx - ydmdemvbev)
-
29 Mar 2018
Phase 2
29
(ptgetmdwwn) = krdqpejujw bwnmvyikpe (bielpnwemx )
Positive
18 Oct 2017
Phase 2
59
(AUY922 Arm)
(uizzducneu) = rjwcfsxtcs mjornvceze (iuuqmqpvpt, vkyqvbachz - uvndnsoqaz)
-
13 Mar 2017
(Chemotherapy Arm)
(uizzducneu) = uvdilzvnyw mjornvceze (iuuqmqpvpt, mfkypagmcq - vehueahhcs)
Phase 2
21
xyxzjosztp(kxpbuuhvku) = vprsprzgts tufzoeqvou (lgitrxplwu, cnppmsdwtn - ehfiaabbwe)
-
23 Jan 2017
Phase 2
25
(rmqhjluhij) = vhygskcjqn oldtfljgok (xqcfxdawsj, ntsuqfzlpf - wlajbnqvwy)
-
04 Oct 2016
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free